Companies will develop assays to screen compounds created by WuXi for Pfizer.

WuXi PharmaTech signed a new three-year, in vitro ADME collaboration agreement with Pfizer. The firms will together establish assays to provide screening services on compounds that WuXi synthesizes for Pfizer.

“A high-quality and flexible Asia R&D partnership network is critical to Pfizer’s emerging market and Asia strategy,” comments Steve Yang, Ph.D., vp and head of Asia R&D. “We want to build strong relationship with leading contract research organizations such as WuXi PharmaTech to tap into the scientific talents and R&D capabilities in Asia.”

WuXi PharmaTech and Pfizer have previously worked together on synthetic chemistry, parallel medicinal chemistry, ADME, and bioanalytical services. “This new agreement further strengthens our already productive relationship with Pfizer, one of our largest customers for many years, and it is the direct result of our research capability and firm commitment to quality and customer satisfaction,” according to Ge Li, Ph.D., chairman and CEO of WuXi PharmaTech.

Previous articleGAO Tek Rolls out Update for TI DSP Evaluation Board
Next articleOnyx Gains Rights to BTG’s Preclinical Anticancer Agent for $13M